ALSAF.PA Safe Orthopaedics Euronext pre-market 10 Feb 2026: -9.37% as cash risk

ALSAF.PA stock opened the Euronext pre-market session down 9.37% to EUR 0.87 on 10 Feb 2026, after a slide from a previous close of EUR 0.96. Trading volume is elevated at 18,778.00 shares versus an average of 7,340.00, signaling outsized selling. The fall follows mixed operational metrics and a very stretched balance sheet, making liquidity and cash runway immediate investor concerns. We summarise key metrics, technicals, Meyka AI grading, and price forecasts to help investors weigh short-term downside against possible recovery scenarios.

ALSAF.PA stock pre-market price action

Today ALSAF.PA stock trades at EUR 0.87 after an open at EUR 0.88 and a previous close of EUR 0.96. The stock hit a day low of EUR 0.84 and a day high of EUR 0.88. Volume is 18,778.00 versus an average of 7,340.00, giving a relative volume of 2.56 and confirming heavier-than-normal selling pressure.

ALSAF.PA stock fundamentals and risks

Safe Orthopaedics SA (ALSAF.PA) is in Healthcare, Medical – Instruments & Supplies, listed on EURONEXT and headquartered in France. Market cap reads EUR 7,936.00. Reported EPS is -9,792.48, and the company shows negative free cash flow per share and a fragile current ratio of 0.03, highlighting tight liquidity.

Key risks include large enterprise value of EUR 270,432,936.00 versus tiny market cap, stretched working capital and long days of inventory at 1,050.82 days. Investors should treat fundamentals as weak until balance-sheet improvements appear.

ALSAF.PA stock technicals and volume

Technicals show RSI 43.84, MACD histogram 0.02, and ADX 37.71, indicating a strong trend and room for continued downward momentum. Bollinger Bands lower band is EUR 0.82, near today’s low, which signals price pressure at the low band. On‑balance volume (OBV) is -24,531.00, aligning with distribution.

Meyka AI rates ALSAF.PA with a score out of 100

Meyka AI rates ALSAF.PA with a score out of 100: 67.89 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects weak liquidity and high enterprise value versus market cap, balanced by niche product offerings in spinal implants and recent pipeline metrics.

This grade is informational and not investment advice.

ALSAF.PA stock outlook and price forecasts

Meyka AI’s forecast model projects a monthly target of EUR 1.06 and a quarterly target of EUR 1.03. Versus the current price of EUR 0.87, the monthly target implies an upside of 21.84% and the quarterly target implies 18.39%. A conservative downside scenario to EUR 0.60 implies a fall of -31.03%. Forecasts are model-based projections and not guarantees.

ALSAF.PA stock trading implications and sector context

Compared with Healthcare peers, ALSAF.PA’s price-to-sales and EV-to-sales metrics are extreme: P/S is 0.00 (very low) while EV/Sales is 46.55, suggesting market cap disconnect from enterprise liabilities. The Healthcare sector’s average current ratio is roughly 2.15, making ALSAF.PA’s 0.03 substantially weaker. Traders should watch liquidity, daily volume spikes, and any corporate updates before increasing exposure.

Final Thoughts

Key takeaways for ALSAF.PA stock in this pre-market session: the share price is EUR 0.87, down 9.37%, with volume at 18,778.00, and clear liquidity stress from a current ratio of 0.03. Meyka AI’s model projects a monthly target of EUR 1.06, implying 21.84% upside, but a realistic downside case to EUR 0.60 is -31.03%. Our Meyka grade (B, score 67.89) balances the company’s niche product line against weak cash metrics and a high enterprise value. For investors, the immediate questions are cash runway and any potential capital raise, which would dilute holders but ease operational risk. Short-term traders may find volatility, while longer-term holders should seek a visible improvement in liquidity, clearer revenue growth and updated guidance before adding exposure. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.